Thermo Fisher Scientific has launched the Invitrogen Evos S1000 spatial imaging system, which enables researchers to produce quality data.
This system allows researchers to generate multiplexed images for several samples in a matter of hours to overcome the constraints of existing fluorescent microscopy technologies.
Go deeper with GlobalData
Employing patented spectral technology, it enables researchers to simultaneously capture images of up to nine various targets.
This capability claims to conserve the integrity of the tissue by minimising the number of imaging rounds required.
Designed for compatibility with a broad array of reagents and antibodies, the Evos S1000 system can be integrated into existing laboratory workflows.
This integration is crucial in meeting the increasing demand for multiplex imaging capabilities in research settings.
Thermo Fisher Scientific flow and imaging technologies general manager and vice-president Trisha Dowling said: “Understanding tissue structure and function is crucial for developing new treatments for solid tumours and neurodegenerative diseases.
“The Evos S1000 delivers a detailed snapshot of tissue microenvironments and architecture in their native state, helping researchers accelerate their experiments, achieve more with their tissue samples and drive advancements in critical research areas.”
The system can scan and stitch a nine-plex image of a 1cm² tissue area at 10× magnification in approximately 20 minutes.
It is sensitive enough to identify complex multiplexed staining patterns in tissues with a 4.2MP, 16-bit scientific complementary metal oxide semiconductor (sCMOS) camera.
It also features variable magnification options and automated routines for image acquisition.
Currently available in Europe and the US, the system offers researchers tools to deepen the understanding of biological systems and contribute to the development of new disease treatments.
In October 2024, Thermo Fisher’s Oncomine in vitro diagnostic test received Food and Drug Administration approval for use as a companion diagnostic in Grade II IDH-mutant glioma.
